- Home
- MNDY vs INCY Comparison
MNDY vs INCY Comparison
Compare MNDY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDY
- INCY
- Stock Information
- Founded
- MNDY 2012
- INCY 1991
- Country
- MNDY Israel
- INCY United States
- Employees
- MNDY N/A
- INCY N/A
- Industry
- MNDY Computer Software: Prepackaged Software
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- MNDY Technology
- INCY Health Care
- Exchange
- MNDY Nasdaq
- INCY Nasdaq
- Market Cap
- MNDY 14.6B
- INCY 13.0B
- IPO Year
- MNDY 2021
- INCY 1993
- Fundamental
- Price
- MNDY $191.95
- INCY $83.10
- Analyst Decision
- MNDY Strong Buy
- INCY Buy
- Analyst Count
- MNDY 24
- INCY 20
- Target Price
- MNDY $310.17
- INCY $80.31
- AVG Volume (30 Days)
- MNDY 1.2M
- INCY 1.7M
- Earning Date
- MNDY 11-10-2025
- INCY 10-28-2025
- Dividend Yield
- MNDY N/A
- INCY N/A
- EPS Growth
- MNDY N/A
- INCY 900.04
- EPS
- MNDY 0.76
- INCY 4.37
- Revenue
- MNDY $1,100,240,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- MNDY $28.81
- INCY $16.26
- Revenue Next Year
- MNDY $22.44
- INCY $11.07
- P/E Ratio
- MNDY $251.73
- INCY $19.02
- Revenue Growth
- MNDY 30.24
- INCY 18.87
- 52 Week Low
- MNDY $166.22
- INCY $53.56
- 52 Week High
- MNDY $342.64
- INCY $87.99
- Technical
- Relative Strength Index (RSI)
- MNDY 43.46
- INCY 49.53
- Support Level
- MNDY $186.59
- INCY $84.54
- Resistance Level
- MNDY $195.10
- INCY $87.10
- Average True Range (ATR)
- MNDY 5.60
- INCY 1.78
- MACD
- MNDY 4.79
- INCY -0.64
- Stochastic Oscillator
- MNDY 85.36
- INCY 5.42
About MNDY monday.com Ltd.
Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.